anti-IL-21

anti-IL-21 (also known as NN-9828, NN-8828, or LAD-328) is a fully human recombinant monoclonal antibody designed to target and neutralize interleukin-21 (IL-21). Originally developed by ZymoGenetics and subsequently acquired and developed by Novo Nordisk, the antibody blocks IL-21 from binding to its receptor, thereby inhibiting downstream JAK-STAT signaling pathways and suppressing the activation, proliferation, and differentiation of T and B cells. Novo Nordisk evaluated the antibody in Phase II clinical trials for type 1 diabetes (in combination with the GLP-1 receptor agonist liraglutide) as well as rheumatoid arthritis, Crohn's disease, and systemic lupus erythematosus, but discontinued development in these indications. In 2024, Almirall licensed the global rights to the antibody (under the code LAD-328) to develop it for immune-inflammatory dermatological diseases, including hidradenitis suppurativa.

Other names

anti-IL-21anti-IL21anti-IL 21anti-interleukin-21anti-interleukin21anti-interleukin 21anti-interleukin-21 monoclonal antibodyanti-interleukin21 monoclonal antibodyanti-interleukin 21 monoclonal antibodymonoclonal anti-IL-21 antibody